Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
RedHill Biopharma Ltd is a drug manufacturers-specialty & generic business based in the US. RedHill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. RedHill Biopharma employs 182 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $2.47 |
|---|---|
| 52-week range | $2.24 - $11.52 |
| 50-day moving average | $3.43 |
| 200-day moving average | $5.83 |
| Wall St. target price | $14.38 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.24 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.47 from 2022-01-14
| 1 week (2022-01-11) | -1.20% |
|---|---|
| 1 month (2021-12-17) | -6.79% |
| 3 months (2021-10-18) | -49.28% |
| 6 months (2021-07-16) | -58.63% |
| 1 year (2021-01-15) | -66.76% |
|---|---|
| 2 years (2020-01-17) | -59.71% |
| 3 years (2019-01-18) | 6.89 |
| 5 years (2017-01-18) | 10.25 |
| Revenue TTM | $85.1 million |
|---|---|
| Gross profit TTM | $28.3 million |
| Return on assets TTM | -28.2% |
| Return on equity TTM | -484.93% |
| Profit margin | -114.75% |
| Book value | $0.25 |
| Market capitalisation | $133.6 million |
TTM: trailing 12 months
We're not expecting RedHill Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, RedHill Biopharma's shares have ranged in value from as little as $2.24 up to $11.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RedHill Biopharma's is 1.7952. This would suggest that RedHill Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.